EUVIMEDEUVIMED entdecken
Crossref

Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists

Juhienah K Khalaf iD, Laura S Bess, Lois M Walsh, Janine M Ward, Craig L Johnson, Mark T Livesay, Konner J Jackson, Jay T Evans, Kendal T Ryter, Hélène G Bazin-Lee

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Juhienah K Khalaf und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inimmune Corporation, 1121 E Broadway, Suite 121, Missoula, Montana 59802, United States. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Adjuvants, Vaccine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: NIAID NIH HHS, U.S. Department of Health and Human Services, Montana Office of Tourism and Business Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most known synthetic toll-like receptor 4 (TLR4) agonists are carbohydrate-based lipid-A mimetics containing several fatty acyl chains, including a labile 3-O-acyl chain linked to the C-3 position of the non-reducing sugar known to undergo cleavage impacting stability and resulting in loss of activity. To overcome this inherent instability, we rationally designed a new class of chemically more stable synthetic TLR4 ligands that elicit robust innate and adaptive immune responses. This new class utilized a diamino allose phosphate (DAP) scaffold containing a nonhydrolyzable 3-amide bond instead of the classical 3-ester. Accordingly, the DAPs have significantly improved thermostability in aqueous formulations and potency relative to other known natural and synthetic TLR4 ligands. Furthermore, the DAP analogues function as potent vaccine adjuvants to enhance influenza-specific antibodies in mice and provide protection against lethal influenza virus challenges. This novel set of TLR4 ligands show promise as next-generation vaccine adjuvants and stand-alone immunomodulators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4Adjuvants, VaccineAnimalsMiceImmunologic FactorsAdjuvants, ImmunologicLigandsAntibodies, Viral

Substanzen

Toll-Like Receptor 4Adjuvants, VaccineImmunologic FactorsAdjuvants, ImmunologicLigandsAntibodies, Viral

Autor:innen und Institutionen

  • Inimmune Corporation, 1121 E Broadway, Suite 121, Missoula, Montana 59802, United States.

ORCID-Profile: Juhienah K Khalaf

Förderung

  • NIAID NIH HHS
  • U.S. Department of Health and Human Services
  • Montana Office of Tourism and Business Development

Zitieren

APA

Khalaf, J. K., Bess, L. S., Walsh, L. M., Ward, J. M., Johnson, C. L., Livesay, M. T., Jackson, K. J., Evans, J. T., Ryter, K. T., & Bazin-Lee, H. G. (2023). Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00724

Vancouver

Khalaf JK, Bess LS, Walsh LM, Ward JM, Johnson CL, Livesay MT, et al. Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00724

BibTeX
@article{Khalaf2023,
  author = {Khalaf, Juhienah K and Bess, Laura S and Walsh, Lois M and Ward, Janine M and Johnson, Craig L and Livesay, Mark T and Jackson, Konner J and Evans, Jay T and Ryter, Kendal T and Bazin-Lee, Hélène G},
  title = {Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00724}
}
Kostenlos starten →